Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isosorbide mononitrate/arginine - Angiogenix

Drug Profile

Isosorbide mononitrate/arginine - Angiogenix

Alternative Names: ACCLAIM

Latest Information Update: 24 Jun 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angiogenix Inc
  • Class Basic amino acids; Diamino amino acids; Essential amino acids; Ischaemic heart disorder therapies; Organic nitrates; Sugar alcohols; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris

Most Recent Events

  • 08 Feb 2005 Data from a media release have been added to the Ischaemic Heart Disease therapeutic trials section
  • 31 Jan 2005 Angiogenix has completed a phase II trial in chronic angina pectoris in 7 countries
  • 29 Jun 2004 Nitrate/arginine is available for licensing (http://www.angiogenix.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top